Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease.

Zambon A, Zhao XQ, Brown BG, Brunzell JD.

Am J Cardiol. 2014 May 1;113(9):1494-8. doi: 10.1016/j.amjcard.2014.01.426. Epub 2014 Feb 11.

2.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
3.
4.

Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.

Airan-Javia SL, Wolf RL, Wolfe ML, Tadesse M, Mohler E, Reilly MP.

Am Heart J. 2009 Apr;157(4):687.e1-8. doi: 10.1016/j.ahj.2009.01.001. Epub 2009 Feb 23.

5.

Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).

Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE.

J Am Coll Cardiol. 2013 Oct 22;62(17):1580-4. doi: 10.1016/j.jacc.2013.07.023. Epub 2013 Jul 31.

7.

Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality.

Pirillo A, Norata GD, Catapano AL.

Curr Pharm Des. 2013;19(21):3841-57. Review.

PMID:
23286430
8.

Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.

Superko HR, Garrett BC, King SB 3rd, Momary KM, Chronos NA, Wood PD.

Am J Cardiol. 2009 Feb 1;103(3):387-92. doi: 10.1016/j.amjcard.2008.09.103. Epub 2008 Nov 27.

PMID:
19166694
9.
10.

Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.

Bays H, Giezek H, McKenney JM, O'Neill EA, Tershakovec AM.

Metab Syndr Relat Disord. 2012 Aug;10(4):260-6. doi: 10.1089/met.2012.0005. Epub 2012 Mar 8.

PMID:
22400810
11.

Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.

Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, Glynn RJ, Ridker PM, Krauss RM.

Circulation. 2015 Dec 8;132(23):2220-9. doi: 10.1161/CIRCULATIONAHA.115.016857. Epub 2015 Sep 25.

12.

HDL-C: role as a risk modifier.

Barter P.

Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6. Review.

PMID:
22152280
13.
14.

Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.

Albers JJ, Slee A, Fleg JL, O'Brien KD, Marcovina SM.

Atherosclerosis. 2016 Aug;251:454-459. doi: 10.1016/j.atherosclerosis.2016.06.019. Epub 2016 Jun 11.

15.
16.

The facts behind niacin.

Hochholzer W, Berg DD, Giugliano RP.

Ther Adv Cardiovasc Dis. 2011 Oct;5(5):227-40. doi: 10.1177/1753944711419197. Epub 2011 Sep 5. Review.

PMID:
21893559
17.

Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.

Chrysant SG, Ibrahim M.

J Clin Hypertens (Greenwich). 2006 Jul;8(7):493-9; quiz 500-1. Review.

18.

What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?

Ahmed MH.

J Cardiovasc Med (Hagerstown). 2010 Nov;11(11):858-60. doi: 10.2459/JCM.0b013e32833dadc3.

PMID:
20686417
19.

Advances in the understanding and management of dyslipidemia: using niacin-based therapies.

Ito MK.

Am J Health Syst Pharm. 2003 Jul 1;60(13 Suppl 2):S15-21; quiz S25.

PMID:
12901026
20.

Supplemental Content

Support Center